Compare SPDR Kensho Final Frontiers ETF (ROKT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Kensho Final Frontiers ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? SPDR Kensho Final Frontiers ETF trades at $100.25 (market cap $165.02M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 30.4× SPDR Kensho Final Frontiers ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, SPDR Kensho Final Frontiers ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Kensho Final Frontiers ETF for 14 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ROKT | TVTX | |
|---|---|---|
Market Cap | $165.02M | $5.02B |
Volume | 15,155 | 2,060,842 |
Sector | Sector/Thematic | Health |
52-Week High | $136.68 | $67.52 |
52-Week Low | $72.93 | $26.79 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROKT (SPDR S&P Kensho Final Frontiers ETF) trades at $101.88, down 1.0% today, with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The ETF provides diversified exposure to aerospace and defense companies, though key financial ratios are currently unavailable. Recent news highlights growing investor interest in space-related investments through diversified vehicles like ROKT rather than individual space stocks.
The ETF offers efficient exposure to the final frontiers theme but faces challenges from high operational costs and profitability timelines in the space sector. Current bearish technical indicators suggest near-term pressure, while long-term growth potential in aerospace and defense remains supported by industry developments.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
